Talphera

Talphera Deferred Tax Liabilities

The Deferred Tax Liabilities of Talphera (TLPH) as of Nov 7, 2026 is 1.35 B USD. In the previous year, Deferred Tax Liabilities was 1.22 B USD — a change of 10.69% (higher).

Deferred Tax Liabilities

1.35 BUSD

YoY

10.69%

Last updated:

Deferred Tax Liabilities of Talphera is 2024 1.35 B USD. Deferred Tax Liabilities of Talphera was 2023 1.22 B USD. It decreases by 10.69% higher compared to the previous year.

The Talphera Deferred Tax Liabilities history

  • 3 Years

  • 10 Years

  • 25 Years

  • Max

Deferred Tax Liabilities
Date
Deferred Tax Liabilities
Jan 1, 2023
1.22 B USD
Jan 1, 2024
1.35 B USD
The Talphera Deferred Tax Liabilities history
YEARDeferred Tax LiabilitiesYoY
1.35 BUSD+10.69%
1.22 BUSD—

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Get Free API Key

Talphera Stock analysis

What does Talphera do? Talphera Inc develops and commercializes therapies for medically supervised settings, focusing on nafamostat-based products. The company's Niyad targets regional anticoagulants for dialysis circuits in acute kidney injury and chronic kidney disease patients. LTX-608 is an intravenous formulation for potential treatment of viral infections, ARDS, DIC, and acute pancreatitis. Pre-filled syringes Fedsyra and PFS-02 are also under development. The firm sells these products to hospitals, dialysis centers, and medical facilities requiring specialized therapies in controlled environments. Niyad is designed for use during continuous renal replacement therapy and hemodialysis procedures, primarily targeting healthcare providers in hospital settings and dialysis centers. LTX-608 aims to address viral and inflammatory conditions, with potential buyers including hospitals treating respiratory and coagulation disorders. The pre-filled syringes Fedsyra and PFS-02 serve as delivery systems for these therapies, appealing to medical institutions needing efficient administration solutions. The company's revenue streams come from the sale of Niyad, LTX-608, Fedsyra, and PFS-02 to healthcare providers. Hospitals and dialysis centers are key buyers for Niyad, while LTX-608 targets hospitals managing viral outbreaks and severe inflammatory conditions. Fedsyra and PFS-02 are sold as complementary products to support the delivery of nafamostat therapies, with demand driven by the need for specialized medical treatments in supervised care settings. Talphera is one of the most popular companies on Eulerpool.

Frequently Asked Questions about Talphera stock

Deferred Tax Liabilities of Talphera is 1.35 B USD in 2024.

Deferred Tax Liabilities of Talphera changed from 1.22 B USD to 1.35 B USD, representing a 10.69% change. The value is higher than the previous year.

On Eulerpool you can find the complete historical development of Deferred Tax Liabilities Talphera since 2006 – with annual values, charts, and detailed analysis.

Deferred tax liabilities arise from temporary differences between accounting and tax treatments. They represent taxes owed in the future on income already recognized.

Deferred Tax Liabilities's USD is a key factor for investors. Changes in this metric can signal improving or deteriorating fundamentals, directly impacting the stock price. On Eulerpool, you can track Deferred Tax Liabilities's Talphera historically and in real time.

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Get Free API Key

Balance Sheet — Talphera

Total AssetsCurrent AssetsCash & EquivalentsReceivablesInventoryProperty, Plant & EquipmentGoodwillIntangible AssetsEquityLiabilitiesDebtCurrent LiabilitiesLong-term DebtShort-term DebtRetained EarningsBook Value per ShareTangible Book Value per ShareWorking CapitalInvestmentsAccounts PayableNon-Current AssetsShort-Term InvestmentsLong-Term InvestmentsNet DebtTreasury StockMinority InterestDeferred Tax LiabilitiesNet Tangible AssetsGoodwill/AssetsIntangibles/Assets

All Key Metrics — Talphera